89 results on '"Ohe, Y."'
Search Results
2. EP.13C.01 Prognosis of Surgically Resected Pure and Combined Small Cell Lung Cancer Undergoing Adjuvant Chemotherapy
3. OA09.05 Subcutaneous vs Intravenous Amivantamab: Patient Satisfaction and Resource Utilization Results from the PALOMA-3 Study
4. EP.12A.31 Clinical Characteristics and Outcomes of EGFR-Positive Non-Small Cell Lung Cancer with Acquired RET Fusions
5. EP.06B.14 Differential Expression in Potential Therapeutic Target Protein by Treatment in Small Cell Lung Cancer with and without Transformation
6. EP11.03-08 Multicenter Pharmacokinetic Study of Pembrolizumab for Non-Small Cell Lung Cancer in Older Adults Aged Over 75 Years
7. 19P Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis
8. EP08.02-173 Treatment Patterns and Outcomes Among Patients With EGFR-mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings
9. EP08.02-016 Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs
10. EP08.02-118 TRUST-II: A Global Phase II Study for Taletrectinib inROS1fusion Positive Lung Cancer and Other Solid Tumors
11. EP07.03-004 Efficacy of Thoracic Radiotherapy for Local Progression in Advanced Thymic Carcinoma
12. FP04.01 Nivolumab 480 mg Every 4 Weeks as De Novo Second-line Treatment for Advanced Non-Small Cell Lung Cancer: CheckMate 907
13. Survey concerning "Anti-Doping" for junior-high-school Judo-players. .
14. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.
15. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.
16. P15.03 A Phase 1/1b Study of Lazertinib as Monotherapy and in Combination with Amivantamab in Advanced EGFR-Mutated NSCLC
17. Block of the sacral segments in lumbar epidural anaesthesia.
18. Distant Failure after Treatment of Postoperative Locoregional Recurrence of Non-Small Cell Lung Cancer
19. Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer
20. Comparative Investigation of End Plate and Limiter Biasing in the Hiei Tandem Mirror
21. Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer
22. A phase I/II trial of cisplatin, docetaxel and ifosfamide in advanced or recurrent non-small cell lung cancer
23. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen
24. Expression vector with DNA of bovine papilloma virus 1 for keratinocyte gene therapy
25. P25.02 Concurrent Chemoradiotherapy With Cisplatin + S-1 for Locally Advanced Non-Small Cell Lung Cancer: IPD Meta-Analysis
26. Effect of nebulized morphine in cancer patients with dyspnea: a pilot study.
27. Phase I study of cisplatin and docetaxel plus mitomycin C in patients with metastatic non-small cell lung cancer.
28. Age related elevation of serum macrophage colony stimulating factor (M-CSF) level
29. Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation
30. Abstracts of scientific papers third international symposium on computing in anesthesia
31. Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line
32. Isolation and Characterization of Novel Antimicrobial Peptides, Rugosins A, B, and C, from the Skin of the Frog, Rana rugosa
33. c-Ha-ras down regulates the alpha-fetoprotein gene but not the albumin gene in human hepatoma cells
34. Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer
35. Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice
36. Cystatin C and apolipoprotein E immunoreactivities in CA1 neurons in ischemic gerbil hippocampus
37. Specific radioimmunoassay of glucitol-lysine — application to lens proteins in streptozotocin-diabetic rats
38. Age-related augmentation of stroke tendency evaluated using plasma P-selectin levels
39. P1.09-11 Influences of Sampling Method to Morphological Feature Measurement of Lung Cancer Cell
40. P1.01-103 Preliminary Results of Brigatinib in Japanese Patients (Pts) Who Previously Received Alectinib: Brigatinib-2001 Study
41. MA11.07 Efficacy of Immune-Checkpoint Inhibitors and EGFR-TKIs in NSCLC Patients with High PD-L1 Expression
42. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers
43. P75.01 Activity of Brigatinib in Alectinib-Resistant ALK-Positive NSCLC According to ALK Plasma Mutation Status From J-ALTA Trial
44. P3.01-30 Treatment Sequencing in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan
45. P1.17-06 Salvage Surgery After Chemotherapy and/or Radiotherapy Including SBRT and Proton: Consecutive Analysis of 46 Patients
46. MA 17.06 Safety Data from Randomized Phase II Study of CDDP+S-1 vs CDDP+PEM Combined with TRT for Locally Advanced Non-Squamous NSCLC
47. OA12.02 Randomized Phase II Study of CDDP+S-1 vs CDDP+PEM Combined with Thoracic RT for Locally Advanced Non-Sq NSCLC: SPECTRA Study
48. OA07.03 Clinical Outcome of Non-Small Cell Lung Cancer with EGFR/HER2 Exon 20 Insertions Identified in the LC-SCRUM-Japan
49. P1.01-102 Actionable Gene Aberration and the Response of Matched Therapy Among Patients with Non-Small-Cell Lung Carcinoma
50. MA15.03 Exploring Digital Pathology-Based Morphological Biomarkers for a Better Patients’ Selection to the Immune Checkpoint Inhibitor of Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.